Brokerages Set Repligen Co. (NASDAQ:RGEN) Price Target at $185.20

Repligen Co. (NASDAQ:RGENGet Free Report) has received an average recommendation of “Moderate Buy” from the thirteen analysts that are covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $185.20.

Several equities analysts have recently issued reports on RGEN shares. Canaccord Genuity Group assumed coverage on Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective for the company. Canaccord Genuity Group assumed coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. Wolfe Research began coverage on shares of Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating for the company. Finally, Royal Bank of Canada restated an “outperform” rating and set a $205.00 target price on shares of Repligen in a research report on Thursday, September 26th.

View Our Latest Analysis on Repligen

Hedge Funds Weigh In On Repligen

Hedge funds and other institutional investors have recently made changes to their positions in the company. UMB Bank n.a. increased its position in shares of Repligen by 138.3% during the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 130 shares in the last quarter. Blue Trust Inc. grew its holdings in shares of Repligen by 113.4% during the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after buying an additional 127 shares in the last quarter. Resources Management Corp CT ADV acquired a new stake in shares of Repligen in the third quarter valued at about $37,000. Quarry LP lifted its stake in shares of Repligen by 796.7% in the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock worth $40,000 after buying an additional 239 shares in the last quarter. Finally, nVerses Capital LLC acquired a new position in Repligen during the third quarter worth about $45,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Price Performance

Shares of RGEN stock opened at $160.51 on Friday. Repligen has a fifty-two week low of $113.50 and a fifty-two week high of $211.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The stock’s 50-day simple moving average is $148.36 and its 200-day simple moving average is $144.64.

Repligen (NASDAQ:RGENGet Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. During the same quarter in the prior year, the company earned $0.23 EPS. Repligen’s quarterly revenue was up 9.7% on a year-over-year basis. On average, analysts forecast that Repligen will post 1.54 EPS for the current year.

About Repligen

(Get Free Report

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Further Reading

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.